India Clinical Nutrition for Cancer Care Market Analysis

India Clinical Nutrition for Cancer Care Market Executive Summary

The India Clinical Nutrition for Cancer Care Market was valued at $102.4 Mn in 2023 and is predicted to grow at a CAGR of 8.04% from 2023 to 2030, to $175.9 Mn by 2030.

Clinical nutrition for cancer care is a specialized field focusing on providing optimal nutritional support to patients throughout their cancer journey. It goes beyond simply “eating healthy” and involves a personalized approach to address the unique nutritional needs of each patient. A registered dietitian or other qualified healthcare professional usually assess the patient’s nutritional status. Based on the assessment, a personalized plan is created to meet the patient’s individual needs. Nutritional deficiencies are prevalent among cancer patients due to treatment side effects, altered metabolism, and decreased appetite. Clinical nutrition interventions play a crucial role in improving treatment tolerance as adequate nutrition can help patients tolerate chemotherapy and radiation therapy better, potentially reducing side effects and allowing for completion of treatment plans. Also, it maintains strength and immunity as proper nutrition helps patients maintain muscle mass, fight infections, and recover faster from surgery. Lastly, it enhances the quality of life since nutritional support can improve fatigue, appetite, and overall well-being, leading to a better quality of life during cancer treatment.

Advancements in medical nutrition therapy have led to the development of specialized oral nutritional supplements (ONS) and enteral feeding formulas. These products provide concentrated nutrients and can be crucial for patients struggling to meet their nutritional needs through regular diet alone. Parenteral nutrition remains an option for patients unable to tolerate oral or enteral feeding. Overall, clinical nutrition for cancer care plays a vital role in optimizing patient outcomes by ensuring they receive the necessary nutrients to support their body throughout treatment.

The India Clinical Nutrition for Cancer Care Markets is driven by significant factors such as the growing cancer burden, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. However, reimbursement policies, lack of awareness, and challenges in implementation restrict the growth and potential of the market.

The major players of the India Clinical Nutrition for Cancer Care Market are Reckitt Benckiser, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.

Market Dynamics

Market Growth Drivers

Growing Cancer Burden: A major driver for this market is the increasing global burden of cancer and the high mortality rates associated with it. As the population ages and lifestyle risks like smoking persist, the number of new cancer cases diagnosed each year continues to rise. According to ICMR, in 2022, the projected number of new cancer cases in India was 1,461,427, with a crude incidence rate of 100.4 per 100,000 individuals. Approximately one in nine people in India is expected to face a cancer diagnosis during their lifetime. Moreover, the projected cancer burden in India is expected to rise from 26.7 Mn DALYs (adjusted mortality to incidence) in 2021 to 29.8 Mn in 2025, with the highest burden in the north and northeast regions. This translates to a larger patient population requiring specialized nutritional support during treatment, which in turn drives the Clinical Nutrition for Cancer Care Market further.

Increasing risk of malnutrition in oncology patients: Malnutrition is a prevalent issue among cancer patients, caused by the disease itself and its treatment side effects such as reduced appetite, nausea, vomiting, diarrhoea, difficulty swallowing. As per the National Cancer Institute, 30% to 85% of cancer patients experience malnourishment during their treatment process. As the risk of malnutrition rises, there’s a corresponding increase in the demand for specialized nutritional support products and services. Thus, the demand increases the Clinical Nutrition for Cancer Care Market.

Advancements in nutritional products: The advancements provide healthcare professionals with a wider range of tools to address the diverse needs of cancer patients. The market is witnessing a surge in the development of immuno-nutrition solutions tailored to bolster the immune system of cancer patients, potentially enhancing treatment efficacy and reducing complications. Incorporating nutrigenomics into clinical nutrition approaches allows for personalized dietary recommendations based on an individual’s genetic makeup, potentially optimizing treatment response and minimizing adverse effects. These developments in nutrition ultimately lead to an expansion in the Clinical Nutrition for Cancer Care Market.

Market Restraints

Varied reimbursement policies: Reimbursement policies for nutritional support products like oral nutritional supplements (ONS) and enteral feeding formulas differ significantly across regions and even within healthcare systems. This can create access disparities for patients, particularly in areas with limited coverage or complex procedures for reimbursement. Thus, due to cost and reimbursement issues, the Clinical Nutrition for Cancer Care Market might not grow to its full potential.

Limited Awareness: While awareness is increasing, not all healthcare professionals may fully understand the significance of clinical nutrition in cancer care. This can lead to underutilization of nutritional support services and a failure to identify patients who could benefit from them. Some patients might not be fully aware of the benefits of proper nutrition during cancer treatment and the available support options. Therefore, the limited awareness can prevent the Clinical Nutrition for Cancer Care Market from growing.

Challenges in Implementation: The trend towards personalized nutrition plans requires adequate resources and support systems to effectively implement these plans for each patient after consideration of many factors. Also, seamlessly integrating clinical nutrition services into existing healthcare workflows can be challenging. This might require changes in practice patterns and fostering collaboration among different healthcare professionals. These changes in the healthcare structure can be hard to incorporate thus acting as a restraint for the Clinical Nutrition for Cancer Care Market.

Regulatory Landscape and Reimbursement Scenario

In India, the primary regulatory body for pharmaceutical sector is the Central Drugs Standard Control Organization (CDSCO) and the Drug Controller General of India (DCGI) is the key official within the CDSCO. The CDSCO consistently works to achieve transparency, accountability, and standardization in its services to guarantee the safety, effectiveness, and quality of medical products that are produced, imported, and distributed throughout the nation. The Drugs & Cosmetics Act, 1940 and Rules 1945 lays out the foundation for ensuring the safety, rights and well-being of patients by regulating the manufacturing, import, sale, and distribution of drugs and cosmetics.

Under this act, CDSCO is responsible for granting license for approved drugs, conducting clinical trials, setting standards for drugs, monitoring the quality of drugs imported into the nation, and coordinating the efforts of State Drug Control Organizations by offering professional advice in an effort to standardize the enforcement of the D&C Act.

India's healthcare reimbursement scenario is complex and evolving, with both public and private players involved. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana is a national public health insurance scheme of the Government of India that aims to provide free access to health insurance coverage for low-income earners in the country. These programs offer cashless or payment benefits for certain illness-related hospital stays in affiliated hospitals. Certain demographics, such as government employees, are eligible for social health insurance programs in several states. Private insurance firms’ voluntary health insurance programs are becoming more popular. Reimbursement decisions are made according to the specific plan purchased and cover surgery, hospital stays, and occasionally, prescription drugs.

Competitive Landscape

Key Players

Here are some of the major key players in the India Clinical Nutrition for Cancer Care Market:

• Reckitt Benckiser
• Nestlé Health Science
• Abbott Nutrition
• B. Braun Melsungen AG
• Fresenius Kabi
• Danone Nutrica
• Baxter International Inc.
• Victus Inc.
• Mead Johnson
• Aymes